Curie.Bio’s Post

🔬🌐 Hugues Contamin, CEO of CYNBIOSE, and Erwan Bezard, CEO of Motac Neuroscience Ltd, recently contributed to an article featured in the journal Le Monde, emphasizing the geostrategic importance of access to primates for scientific and medical research. In this interview, Hugues Contamin and Erwan Bezard share a common vision regarding the need to establish a national strategy promoting access to this resource essential for European scientific sovereignty.  Without such strategy, research companies like CYNBIOSE and Motac Neuroscience Ltd have secured their long-term supplies through direct agreements with breeding centers. This enables them to offer a unique preclinical service for the asessment of biodistribution, efficacy and toxicity of innovative therapies targeting the #CNS, especially #genetherapies and #ASOs. You can find the full article here 👉 https://bit.ly/49bKat1

A fascinating panel discussion today on the use of #spatialbiology in drug discovery and development. Thank you Dana A M Mustafa for chairing and the experienced panel of Alain van Gool, Mischa Houtkamp, Roderick Beijersbergen and William McTavish for all your contributions Topics covered included: • The importance of spatial biology in drug discovery • Examples of the spatial techniques used in practice / laboratories • Targeted therapy and drug mechanism of action • Challenges in the field • Future directions #spatialbiologycongress Erasmus MC X-omics Genmab Lunaphore

AlveoGene’s Mission is to transform respiratory disease outcomes using inhaled gene therapy.     Our #InGenuiTy® platform enables us to deliver our proprietary self-inactivating lentiviral vector based products directly to the lung via nebulisation treating disease locally, efficiently, and safely where it’s clinical impact and patient benefit can be the greatest. We focus on respiratory diseases of high value and unmet medical need, developing first-in-class and best-in-class products including Alpha-1 Antitrypsin Deficiency (AATD), Neonatal Profound Surfactant Protein Deficiencies (SP-B and ABCA3), and Idiopathic pulmonary Fibrosis (IPF). Ahead of Rare Disease Day this Thursday, please join the Oxford-Harrington 2024 Rare Disease Day Webinar hosted on Wednesday, Feb. 28, 2024, from 10:00 – 11:00 a.m. EST/3:00 p.m. to 4:00 p.m. GMT by clicking the link below. @HarringtonDI_UH @OHRareDisease

Symposium on neutron scattering highlighted possibilities to advance drug discovery! The IPDD symposium on neutron scattering in May aimed to highlight ongoing research and possibilities with neutron scattering in drug design, discovery and formulation, and gathered around 25 researchers from Lund and Copenhagen as well as international speakers joining via zoom. Organisers Raminta Venskutonytė from the Medical Faculty at Lund University, and Zoë Fisher from ESS, reflect on the outcomes of the event. – The symposium provided good opportunities for participants to talk and network, with ample opportunities for in-depth conversations, says Raminta Venskutonytė, associate researcher at Medical Structural Biology, Lund University, and leader of the Structure-based Drug Design (SBDD) working group. – It was great to be able to highlight how neutrons fill an important gap in the drug discovery pipeline, and how they can be used as part of drug target validation, and drug discovery, shedding light on how ligands or drugs interact with their target. Finally, neutrons also have an application in optimizing drug formulation for efficient drug delivery, says Zoë Fisher. Zoë Fisher Vito Foderà Karin Lindkvist Raminta Venskutonytė https://lnkd.in/dtt-hf7F

🏆 2023 EHE Foundation Research Grant Awards 👉 Ajaybabu Pobbati, PhD, Cleveland Clinic Lerner Research Institute, "Harnessing FDA-approved drugs to gain mechanistic insight into the regulation of the TAZ-CAMTA1 fusion protein" WHY THIS MATTERS: Ultimately, the project aims to find an FDA-approved drug with a good safety profile that could treat unresectable, aggressive EHE. 👉 Munir Tanas, MD, University of Iowa, "Creation and Characterization of an EHE Extended Primary Cell Culture" WHY THIS MATTERS: This project addresses a fundamental limitation in EHE science, lack of cells for research. When patients donate to the EHE Biobank, samples are sent to key research partners, like Dr. Tanas, who use them to create EHE cell models or lines to help improve the quality and pace of EHE research. 🔗 Learn more about the 2023 EHE Foundation Research Grants: https://lnkd.in/eRT5EXFE The EHE Foundation thanks the donors who generously give to fund impactful EHE research, our Advisory Board and invited expert reviewers for their time, and EHE patients and families whose participation makes this and other research possible. #EHE #epithelioidhemangioendothelioma #ultrararesarcoma #EHEFoundation #theEHEFoundation #EHEcancer #justlive #sarcoma #raredisease #research #EHEresearch

Looking forward to seeing some known faces and meeting some new ones! Investing? How commercially viable is the science? What are the product development/CMC and regulatory risks? What is the competitive landscape? Fundraising? Does your pitch deck and data room position your company to be as investable as possible? Promising non-clinical data? How to turn that into a commercial product? What is the best product development and regulatory strategy? Growing pains? Addressing the various resource gaps in regulatory affairs, regulatory operations, clinical operations, clinical and medical affairs, regulatory and medical writing and many more as you transition the product from one phase to another! It has been great to work with innovators and the leaders to help them advance their asset and materialize the vision! Looking forward to connecting further to brainstorm solutions with you! #TexasLifeSciencesSummit #CPRIT #THBI

The Automation of Adeno-Associated Virus (AAV) Analytics Workflow Incorporating automation into AAV research and development, tremendous advantages have been realized, allowing scientists to expedite their work and achieve groundbreaking discoveries. If you want to learn more on how Bio-techne automated immunoassay platform can help you to achieve groundbreaking advancements in therapeutic interventions and advancements in AAV analytical tools dont forget to register for the upcoming webinar. The webinar will walk you through the tools and reagents to: - enhance efficiency - improved accuracy - scale-up capabilities - cost effectiveness, - accelerated innovation - improved reproducibility Join Bio-techne to revolutinize and redefine the future of gene therapy. https://lnkd.in/dHUCzvpf #aav #immunoassay #genetherapy #automatedsolutions

📣We are delighted to announce the completion of a global collaboration agreement with the Shanghai Model Organisms Center (SMOC). This five-year agreement extends the existing partnership and will provide unique immuno-oncology platforms and services from all Crown Bioscience facilities worldwide. This strategic alliance includes: ✅The purchase and supply of a broad range of genetically engineered mouse models, including thousands of knock-in and knock-out humanized models, ✅Genetically engineered cell line development services, ✅Custom development of GEMM models and MuPrime™ (our tumor homograft models) leveraging SMOC-engineered mice. Globally, Crown Bioscience research affiliates will benefit from uniform pricing, comprehensive IP protection, and licensing rights. This uniformity is accompanied by a shared commitment to research excellence, unrivaled quality standards, and scientific innovation. Read more about this agreement ➡️ https://hubs.la/Q02yp5vv0 #Bioscience #Biotech #ImmunoOncology #Innovation Shanghai Model Organisms Center, Inc.

Here a refreshed version of our company video talking about our company and the services we offer: Radioligand Binding, Receptor Autoradiography and Occupancy, Cellular Uptake & Release, SPR and Functional Assays. Visit our website to find out more and get in touch if you want to discuss details of your project. https://lnkd.in/d4_749u #receptorpharmacology #ligandbinding #neuroscience #drugdiscovery #targetvalidation #research #researchanddevelopment

I'm pleased to share our latest publication at JACS, "Reversibly Reactive Affinity Selection Mass Spectrometry Enables Maturation of Covalent Peptides," which is the result of a collaboration between Calico Life Sciences and the Brad L. Pentelute lab at the Massachusetts Institute of Technology. We introduce a novel method for enriching covalent reactive peptides from synthetic libraries. As proof of principle, we successfully matured covalent peptide binders against two proteins: HPV16 E6 and Pin1. This approach paves the way for new advancements in peptide therapeutics, offering a promising pathway to creating more effective and selective binders. Read the full paper here: https://lnkd.in/gshgMT3y #JACS #PeptideTherapeutics #CovalentPeptides #Research #Science #MIT #CalicoLifeSciences